Related Experiment Video
Updated: Sep 18, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Stepped-Care Management of Insomnia: Treatment Choices Guided by a Patient Decision Aid in a Pragmatic Nonrandomized
Janet M Y Cheung1,2,3, Lee M Ritterband4, Si-Jing Chen2,5,6
1School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Abstract:
Patients with insomnia face difficult decisions when choosing between treatment options with competing risk-benefit profiles. Patient treatment choices were evaluated as part of a pragmatic nonrandomized clinical trial for a two-step cognitive behavioural therapy for insomnia (CBT-I) intervention. Upon enrollment, participants were guided by a patient decision aid (PtDA), outlining the risk-benefit profiles of medication, face-to-face CBT-I (FtFCBT-I), and digital CBT-I (dCBT-I). In Step 1, participants chose between dCBT-I alone, combined dCBT-I plus medication or medication alone. Non-remitters who enrolled into Step 2 chose between FtFCBT-I, medication, or no additional treatment. A secondary analysis was conducted evaluating patient treatment choices, the presence of decisional conflict, and the acceptability of the PtDA. In Step 1, 47.4% (n = 73) of participants chose dCBT-I, followed by combined dCBT-I plus medication (42.3% n = 66) and medication alone (9.74%; n = 15). The dCBT-I group was less likely to use medications or used them less frequently compared to the other treatment groups. Men and individuals less motivated to change sleep habits were more likely to choose medication in Step 1. In Step 2, 60.9% (n = 42) of non-remitters chose FtFCBT-I, followed by no additional treatment (23.6%; n = 16) and medication (15.9%; n = 11). Non-remitters from the medication group in Step 1 were more likely to choose medication again in Step 2. Over 90% of participants across both treatment steps endorsed the PtDA as acceptable and facilitated their decision-making. This corroborated with the minimal decisional conflict observed, highlighting a potential role in further developing and integrating patient decision aids into practice. Trial Registration: NCT03633305.
More Related Videos
Related Concept Videos
Management of Insomnia
Insomnia
Multiple factors contribute...
Blind Procedures
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

